FDA 483 - Hubei Biocause Heilen Pharmaceutical Co., Ltd. - November 14, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. in Jingmen, China, received a Form FDA 483 with four observations during an inspection from November 10-14, 2025. The firm was cited for inadequate maintenance of API manufacturing equipment, insufficient evaluation of cleaning effectiveness, deficient system performance qualification, and failure to adequately evaluate drug product testing instruments. These findings highlight significant concerns regarding the firm's control over its manufacturing processes and quality systems for Active Pharmaceutical Ingredients.
- Inspection Date
- November 14, 2025
- Product Type
- Drugs
ID · d315b3a5-5ab7-476c-88e7-9b501e7eaf43